Normal foetal kidney volume in offspring of women treated for gestational diabetes by Hokke, Stacey et al.




Received:	1	March	2019  |  Revised:	2	June	2019  |  Accepted:	12	August	2019
DOI: 10.1002/edm2.91  
O R I G I N A L  A R T I C L E
Normal foetal kidney volume in offspring of women treated for 
gestational diabetes
Stacey Hokke1 |   Natasha de Zoysa1 |   Bethany L. Carr2 |   Veronica Abruzzo2 |    
Peter R. Coombs3,4 |   Carolyn A. Allan5,6,7 |   Christine East2,8 |   Julie R. Ingelfinger9 |   
Victor G. Puelles1,10,11 |   Mary J. Black1 |   Danica Ryan1 |   James A. Armitage1,12 |    





























This work was supported by Diabetes 
Australia	(LC‐M.,	Y15G‐CULL).	Diabetes	
Australia	had	no	role	in	the	study	design,	
data collection, analysis, interpretation or 
the writing of the manuscript.
Abstract
Aims: The worldwide prevalence of gestational diabetes mellitus (GDM) is increasing. 
Studies in rodent models indicate that hyperglycaemia during pregnancy alters kid‐
ney development, yet few studies have examined if this is so in humans. The objec‐
tive of this study was to evaluate the association of treated GDM with foetal kidney 
size.
Materials and Methods: Participants	were	recruited	from	an	Australian	tertiary	hos‐
pital, and clinical data were collected from women without GDM and women diag‐




percent of GDM women were diagnosed with fasting hyperglycaemia, while 89% 
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1  | INTRODUC TION
The prevalence of gestational diabetes mellitus (GDM), defined as 
any degree of glucose intolerance with onset or first recognition 
during pregnancy,1 is increasing,2,3 and affects up to 20% of preg‐
nancies. Prevalence rates vary due to local screening practice and di‐
agnostic criteria as well as population characteristics such as obesity, 
maternal age, Type 2 diabetes and ethnicity.4	GDM	can	have	short‐	
and	long‐term	implications	for	both	maternal	and	infant	health.5,6
In humans, kidney development begins around week 5 of 
gestation with the first nephrons formed at gestational week 9. 
Nephrogenesis	 continues	 until	 approximately	 34‐36	weeks	 gesta‐
tion,7 generating the entire complement of nephrons for life. There 
is evidence that low nephron number is associated with renal disease 
in adulthood,8‐11 with a multitude of animal studies identifying that 
a	20%‐30%	reduction	in	nephron	number	is	important.12‐15 Precise 
and accurate estimation of nephron number by noninvasive methods 
is not currently feasible, although a direct relation between foetal 
weight and kidney size,16 birth weight and kidney function,17,18 and 
between kidney mass and total nephron number19,20 has been re‐
ported.	As	renal	mass	is	proportional	to	renal	volume	in	infants,	kid‐
ney volume is currently considered a surrogate measure of nephron 
number.19,21 This concept is supported by findings that smaller foetal 
kidney	size	is	associated	with	lower	kidney	function	in	school‐aged	
children,22 that both low birth weight and Indigenous offspring, who 
are at increased risk of renal disease, present with lower kidney vol‐
umes at birth,23‐25 and that lower childhood kidney volume is associ‐
ated with reduced kidney function.26‐28
Evidence from animal studies indicates that maternal hyper‐
glycaemia can be detrimental to renal development and kidney 
function in exposed offspring.12,29,30 GDM is usually detected in 
mid‐pregnancy	(typically	at	24‐28	weeks	gestation)	by	routine	pop‐
ulation screening.31 The period between onset, and diagnosis and 
treatment, coincides with a period of rapid nephron formation and 
kidney growth.32,33 In humans, renal dysfunction and disease have 
been reported in adults whose mothers had Type 1 or Type 2 diabe‐
tes.34‐37 Despite the high prevalence of GDM, only a handful of stud‐
ies have examined kidney development or renal function in offspring 
of women with GDM.
Available	 data	 from	 reports	 of	 kidney	 volume	 in	 offspring	 of	
mothers with GDM are extremely limited and contradictory. While 
one study found normal foetal kidney volume in diabetic pregnancies 
(pregestational diabetes and GDM pregnancies grouped together),38 
another found increased foetal kidney volume in pregnancies of 
women with GDM.39	 A	 third	 preliminary	 study	 reported	 reduced	
renal	cortical	volume	and	increased	albumin	excretion	in	3‐year‐old	
children whose mothers had GDM, taken to suggest a reduction in 
nephron endowment and glomerular impairment.40
Overall, evidence for the extent to which GDM affects develop‐
ing human kidneys is not robust. It is unclear what effect a period of 
hyperglycaemia has on foetal kidney development and growth, and 
subsequent renal physiology and function. While treatment of GDM 
to control glucose levels can reduce the risk of some adverse peri‐
natal and infant outcomes,41‐43 evidence of treatment benefits are 
often unsupported,43,44 and there is uncertainty regarding optimal 
diagnostic thresholds and optimal glycemic targets.45 The objective 
of this study was to evaluate the association of treated GDM with 
foetal kidney size in late pregnancy.
2  | MATERIAL S AND METHODS
2.1 | Study design and subject recruitment
This	study	was	conducted	between	June	2013	and	August	2016	at	
Monash Medical Centre, a large public university teaching hospital 
in	metropolitan	Melbourne,	Australia,	with	over	4000	births	annu‐
ally.	All	procedures	were	approved	by	the	Monash	University	Human	
Research Ethics Committee and the Monash Health Human Research 
Ethics	Committee	 (13041B).	Academic	 research	 staff	 attended	on	
average one routine pregnancy clinic and one diabetic pregnancy 
clinic	 per	 week	 during	 the	 recruitment	 period.	 Four	 hundred	 and	
thirty‐five	women	with	a	singleton	pregnancy,	aged	18‐40	years	and	
who spoke English were approached by academic research staff. 
Written informed consent was obtained from 169 women to meas‐
ure	 foetal	kidney	volume	at	32‐34	weeks	gestation	by	ultrasound.	




similar in women with and without GDM. Estimated foetal weight, foetal kidney di‐
mensions, total foetal kidney volume and birth weight were similar in offspring of 
women with and without GDM.
Conclusions: We conclude that a period of mild hyperglycaemia prior to diagnosis of 
GDM and treatment initiation, which coincides with a period of rapid nephron forma‐
tion	and	kidney	growth,	does	not	alter	kidney	size	at	32‐34	weeks	gestation.
K E Y W O R D S
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results	and	treatment,	pre‐existing	medical	and	obstetric	conditions	
(eg	 pregnancy‐induced	 hypertension,	 thyroid	 disorder),	 birth	 and	
neonatal outcomes (gestational age from early ultrasound estimates 
and date of last menstrual period, mode of birth, birth weight, birth 
centile,	and	1	and	5	minute	Apgar	scores).
Of the 169 women recruited, 64 women without GDM and 64 
women diagnosed with GDM participated. Overall, 24% (n = 41/169) 
of women enrolled in the study did not have an ultrasound at 
32‐34	weeks,	most	often	due	 to	 scheduling	 issues.	A	 summary	of	
participant	participation	and	data	collection	is	presented	in	Figure	1.	
Women	with	pre‐existing	diabetes	were	excluded.	No	women	had	
renal anomalies or kidney disease.
Gestational diabetes mellitus was diagnosed by a routine 75 g 
oral	glucose	tolerance	test	(OGTT)	at	24‐28	weeks	gestation	if	fast‐
ing	plasma	glucose	was	≥5.5	mmol/L	and/or	2‐hour	plasma	glucose	
was	≥8.0	mmol/L.46 One abnormal value was sufficient for diagnosis. 
Women with normal OGTT values were considered not to have di‐
abetes. Women with and without GDM received routine antenatal 
care. In addition to routine antenatal care, women diagnosed with 
GDM received specialist support for glucose monitoring, diet and 
exercise and were made aware of the risks associated with GDM. 
They were provided information on home glucose monitoring to be 
performed	 on	 3‐4	 occasions	 per	 day.	 Women	 attended	 frequent	
clinic review with a diabetes physician and were typically seen every 
1‐2	weeks	until	birth,	dependent	on	clinical	indication.	Insulin	ther‐




High‐resolution	 obstetric	 ultrasound	 imaging	 was	 performed	 be‐
tween 32 and 34 weeks gestation by qualified sonographers using a 
Philips	iU22	xMatrix	ultrasound	system.	As	per	standard	Australian	
practices,	estimated	foetal	weight	(EFW)	was	calculated	from	meas‐
urements	 of	 bi‐parietal	 diameter,	 head	 circumference,	 abdominal	
circumference and femur length (Hadlock IV).48	Umbilical	artery	pul‐
satility index, middle cerebral artery pulsatility index and amniotic 
fluid index were also recorded. Right and left foetal kidney dimen‐
sions (length, width [mediolateral diameter] and depth [anteropos‐
terior	 diameter])	 were	 measured	 (intra‐observer	 variability	 4.4%).	
Foetal	kidney	volume	was	calculated	as	the	approximation	of	a	pro‐
late ellipsoid (volume = length × width × depth × 0.523) and total 
(combined left and right) kidney volume determined.38
2.3 | Statistical analyses
We considered a 20% difference in foetal kidney volume to be bio‐
logically relevant. Prior to the present study, a sample size calculation 
based on published values for male and female foetal kidney volume 
in late pregnancy (>25 weeks gestation)38 was conducted. We cal‐
culated that 44 female and 54 male participants were required to 
detect a 20% difference in foetal kidney volume between groups, 
respectively. Power calculations conducted a posteriori on the kid‐
ney volume measurements obtained in the present study indicated 
a sample size of n = 50 in both groups was sufficient to detect a 
20%	difference	(1	−	β = 0.8). The 64 participants in each group were 
powered to 0.89 to detect a 20% difference in foetal kidney volume.
Data were analysed using stata 15 statistical software.49 Data were 
initially	tested	for	normality	using	Shapiro‐Wilk	tests.	Descriptive	sta‐
tistics were used to compare maternal and offspring characteristics of 
normal	 and	GDM	pregnancies:	Wilcoxon	 rank‐sum	 test	 or	 indepen‐
dent‐samples	t	test	was	used	to	compare	means,	and	chi‐square	test	or	
test of proportions were used to compare proportions, as appropriate. 
To assess the role of GDM treatment type (diet and exercise alone, or 





in women receiving insulin therapy; analyses of foetal characteristics 
between	 No‐GDM,	 GDM‐Diet	 &	 Exercise	 and	 GDM‐Insulin	 were	
therefore	 adjusted	 for	 gestational	 age	 using	 ANCOVA	with	 Tukey's	
post	hoc	test.	Unadjusted	linear	regressions	were	performed	to	assess	
relationships between total foetal kidney volume and maternal and 
foetal characteristics. Multiple regression analysis was also performed, 
adjusting for relevant potential confounders identified in the above 
group and correlation analyses. Multicolinearity was checked using 
variance inflation factor. P < .05 indicates statistical significance.
3  | RESULTS
3.1 | Maternal characteristics
Maternal characteristics of the total study cohort are presented in 
Table	1.	As	expected,	women	with	GDM	had	significantly	higher	fast‐
ing	and	2‐hour	glucose	levels	at	their	routine	OGTT	at	24‐28	weeks	F I G U R E  1   Participant flow diagram
169 enrolled 
41 did not participate
25 No-GDM
23 ultrasound not scheduled, 
1 ultrasound cancelled, 
1 withdrew 
16 GDM
13 ultrasound not scheduled, 
3 did not attend ultrasound
128 participated 
64 No-GDM, 64 GDM
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gestation as compared to nondiabetic women. Only 30% of GDM 
women (n = 19/64) were diagnosed with fasting hyperglycaemia; thus, 
the mean fasting glucose level for GDM women was below the diag‐
nostic	threshold.	Eighty‐nine	percent	(n	=	57/64)	had	an	elevated	2‐
hour glucose level (one abnormal OGTT value was deemed sufficient 
for	diagnosis).	There	were	no	differences	in	maternal	weight,	BMI,	age	




cations were uncommon and are presented in Table 1.
Comparison of maternal characteristics among GDM women re‐
quiring	insulin	therapy	(GDM‐Insulin;	n	=	22,	34%)	to	GDM	women	
treated	by	diet	 and	exercise	 alone	 (GDM‐Diet	&	Exercise;	 n	=	42,	
66%) identified that women requiring insulin had higher fasting and 
2‐hour	 glucose	 levels	 during	 the	OGTT	 (Table	 1).	 Other	maternal	
characteristics did not differ by treatment modality.
3.2 | Foetal biometry and foetal kidney size at 
32‐34 weeks
Foetal	 characteristics	 as	 measured	 by	 obstetric	 ultrasound	 at	
32‐34	weeks	gestation	are	presented	in	Table	2.	Foetal	biometry,	
amniotic fluid index and umbilical artery pulsatility index were 
similar among foetuses of women with and without GDM, as was 
gestational age at ultrasound (P = .25). Mean values of foetal mid‐
dle cerebral artery pulsatility index were lower in GDM pregnan‐
cies,	 although	 all	 values	were	within	 the	normal	 range.	 Left	 and	
right foetal kidney dimensions and volumes were similar in foe‐
tuses of pregnant women with and without GDM. There was no 
difference in total foetal kidney volume between groups, includ‐
ing	after	adjustment	for	EFW	or	foetal	abdominal	circumference.	
Estimated foetal weight (P = .18) and total kidney volume (P = .21) 
did not differ by sex.
Biometry	 and	kidney	 size	 in	 foetuses	of	women	with	GDM	by	
treatment	method	are	also	presented	in	Table	2.	Ultrasounds	were	
performed on average half a week earlier in GDM women requir‐
ing insulin therapy; analyses were therefore adjusted for gestational 
age. Middle cerebral artery pulsatility index was lower in GDM 
women treated by diet and exercise alone compared to nondiabetic 
pregnancies.	All	other	biometry	and	kidney	measurements	were	sim‐
ilar in foetuses of GDM women, irrespective of maternal treatment.
3.3 | Associations between total foetal kidney 
volume and maternal and foetal characteristics
Unadjusted	 regression	coefficients	 for	 the	entire	 sample	are	pre‐
sented in Table 3. Maternal OGTT glucose levels were not associated 
TA B L E  1   Maternal characteristics and medical/obstetric complications
 
No‐GDM 
(n = 64) GDM (n = 64) Pa
GDM‐Diet & 
Exercise (n = 42)
GDM‐Insulin 
(n = 22) Pb
Maternal characteristics
OGTT	fasting	glucose,		mmol/L 4.30 (0.32) 4.84 (0.71) <.0001 4.62 (0.60) 5.28 (0.72) <.0001†,‡,§ 
OGTT	2‐h	glucose,	mmol/L 5.69 (1.17) 8.84 (1.48) <.0001 8.73 (1.23) 9.06 (1.89) <.0001†,‡,§ 
Weight at hospital booking, kg 66.4 (14.4) 65.3 (18.1) .38 63.0 (11.5) 70.2 (26.2) .23
BMI	at	hospital	booking,	kg/m2 24.23 (4.5) 24.9 (6.5) .90 24.2 (4.0) 26.5 (9.5) .22
Age	at	conception,	y 31.3 (4.5) 31.4 (4.7) .62 31.9 (4.0) 30.1 (5.6) .30
Nulliparous, n (%) 27 (42.2) 34 (53.1) .22 21 (50.0) 13 (59.1) .35
Caucasian ethnicity, n (%) 34 (53.1) 16 (25.0) .001 12 (28.6) 4 (18.1) .004
Maternal medical and obstetric complications
History of GDM, n (%) 2 (3.1) 2 (3.1) 1.0 1 (2.4) 1 (4.5) –
Pre‐eclampsia,	n	(%) 2 (3.1) 1 (1.6) – 1 (2.4) 0 –
Pregnancy‐induced	hypertension,	n	(%) 1 (1.6) 0 – 0 0 –
Pre‐existing	hypertension,	n	(%) 1 (1.6) 2 (3.4) – 1 (2.4) 1 (4.5) –
Polyhydramnios, n (%) 1 (1.6) 1 (1.6) – 1 (2.4) 0 –
Polycystic ovarian syndrome, n (%) 2 (3.1) 1 (1.6) – 1 (2.4) 0 –
Thyroid disorder, n (%) 8 (12.5) 4 (6.3) .74 3 (7.1) 0 –
Note: Values are mean (SD) except where indicated otherwise.
Abbreviations:	BMI,	body	mass	index;	OGTT,	oral	glucose	tolerance	test.
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with total foetal kidney volume. Kidney volume was positively asso‐
ciated with maternal Caucasian ethnicity, parity and foetal biometry 
measures. Multivariable regression analysis was performed relating 
total foetal kidney volume to maternal OGTT glucose levels and ad‐
justing	for	maternal	Caucasian	ethnicity,	parity	and	ultrasound‐es‐
timated foetal weight (R2 = .089, P = .006, Table 4). Estimated foetal 
weight had a significant positive regression coefficient (β = 0.210, 
P = .02). Maternal characteristics did not contribute to the model.
3.4 | Birth outcomes
Birth	outcomes	are	presented	in	Table	5.	Birth	weight	trended	lower	
in neonates of women with GDM (P = .07); women with GDM gave 
birth	approximately	3‐4	days	earlier	than	nondiabetic	women.	There	
were no differences in the rate of labour induction (P = .59) or cae‐
sarean births between groups. The proportion of neonates with 
birth	weights	above	the	90th	centile	(large	for	gestational	age;	LGA)	
or below the 10th centile (small for gestational age) were also similar. 
Male neonates were heavier than female neonates at birth (mean 
(SD): male 3397 (472) g; female 3208 (404) g; P = .02), although no 




The present study of pregnant women with and without GDM indi‐
cated that foetal kidney size was normal among foetuses of women 
with GDM. Our further analyses of foetal kidney development re‐
vealed no differences in kidney dimensions between foetuses of 
women with GDM who required insulin therapy and to those of 
nondiabetic	 women.	 By	 investigating	 the	 continuous	 relation	 be‐
tween OGTT glucose profiles and total foetal kidney volume, we 
also observed that kidney volume was normal in foetuses of women 
who had higher glucose levels at diagnosis. Our findings suggest 
that exposure to a limited period of hyperglycaemia prior to diag‐
nosis and treatment of GDM does not perturb foetal kidney size at 
32‐34	weeks	of	gestation,	a	favourable	finding	given	the	increasing	
number of women diagnosed with GDM.
TA B L E  2  Foetal	biometry	and	foetal	kidney	size
 
No‐GDM 
(n = 64) GDM (n = 64) Pa
GDM‐Diet & 
Exercise (n = 42)
GDM‐Insulin 
(n = 22) Pb
Foetal	biometry
Gestational age, wk 32.9 (0.7) 32.6 (0.7) .25 32.9 (0.7) 32.4 (0.5) .01‡,§ 
Estimated	foetal	weight	(EFW),	g 2158.0 (248.5) 2093.2 (277.3) .17 2154.0 (248.2) 1993.2 (234.4) .27
EFW	percentile,	median	(IQR) 55	(39‐76) 45	(25‐82) .29 50	(26‐83) 38	(23‐62) .23
Abdominal	circumference	(AC),	cm 29.5 (1.4) 29.1 (1.7) .17 29.5 (1.5) 28.4 (1.8) .14
Amniotic	fluid	index 16.0 (3.7) 15.1 (3.8) .09 15.4 (3.7) 14.6 (4.0) .20
Umbilical	artery	pulsatility	index 1.01 (0.28) 1.04 (0.37) .76 1.04 (0.41) 1.04 (0.24) .62
Middle cerebral artery pulsatility index 2.13 (0.40) 1.95 (0.33) .007 1.93 (0.31) 1.99 (0.37) .02† 
Foetal	kidney	dimensions	and	volumes
Right kidney length, cm 4.07 (0.53) 3.98 (0.55) .55 4.06 (0.59) 3.89 (0.42) .47
Right kidney width, cm 2.32 (0.38) 2.25 (0.37) .24 2.26 (0.33) 2.23 (0.32) .41
Right kidney depth, cm 2.24 (0.28) 2.17 (0.38) .30 2.19 (0.38) 2.11 (0.48) .31
Right kidney volume, cm3 11.42 (4.31) 10.48 (4.02) .20 10.78 (3.98) 9.96 (4.11) .35
Left	kidney	length,	cm 3.93 (0.48) 3.98 (0.44) .31 4.01 (0.44) 4.00 (0.38) .63
Left	kidney	width,	cm 2.24 (0.37) 2.28 (0.39) .43 2.16 (0.39) 2.24 (0.32) .71
Left	kidney	depth,	cm 2.18 (0.30) 2.19 (0.32) .92 2.19 (0.34) 2.18 (0.30) .89
Left	kidney	volume,	cm3 10.25 (3.43) 10.12 (3.50) .80 10.17 (3.77) 10.00 (3.14) .97
Total kidney volume, cm3 21.28 (7.58) 20.47 (7.26) .52 21.09 (7.22) 18.98 (7.52) .79
Total	kidney	volume:	EFW	ratio	(cm3/kg) 9.96 (3.38) 9.83 (3.45) .84 9.66 (3.21) 10.38 (3.24) .96
Total	kidney	volume:	AC	ratio	(cm3/cm) 0.72 (0.25) 0.70 (0.24) .78 0.71 (0.24) 0.73 (0.24) .94
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It is important to note that the participating women in this study 
had relatively mild GDM, as few were diagnosed with fasting hy‐
perglycaemia and few required insulin. The diagnosis of GDM at 
Monash Medical Centre was modified towards the end of the pres‐
ent study to incorporate the new guidelines for GDM diagnosis as 
recommended	by	The	Australasian	Diabetes	 in	Pregnancy	Society	
(fasting	 plasma	 glucose	 ≥5.1	 mmol/L	 and/or	 2‐hour	 plasma	 glu‐
cose	 ≥8.5	 mmol/L).50 The data presented here describe women 
classified only by the original set of criteria (fasting plasma glucose 
≥5.5	mmol/L	or	2	hours	plasma	glucose	≥8.0	mmol/L).	Interestingly,	
upon reclassification, none of the 64 control women would have 
been diagnosed with GDM, yet 27% of GDM mothers would no lon‐
ger have been diagnosed as such if the new criteria were applied to 
our study, highlighting the fact that our cohort included a number of 
women with mild or ‘borderline’ dysglycemia. It should be noted that 
supplementary analyses following reclassification of participants 
with the new diagnostic criteria did not alter offspring outcomes or 
our findings (data not shown).
Overall, women identified as having GDM and who participated 
in this study were an engaged and motivated group who regularly at‐
tended clinic, and were typically seen by a diabetes physician every 
1‐2	weeks	until	 birth,	 dependent	on	 clinical	 indication.	 Post‐treat‐
ment glucose profiles were monitored by clinicians but were not 
consistently reported in clinical notes. However, all GDM women 
were managed and treated to normalize their blood glucose levels 
and	may	be	 regarded	as	having	generally	well‐controlled	diabetes,	
with only one third requiring insulin. The effective management of 
GDM was further evident given the absence of foetal overgrowth, 
even after allowing for earlier delivery of mothers with GDM. This 
study is therefore an important assessment of how mild treated 
GDM affects kidney size, rather than an assessment of GDM per se. 
Further	studies	assessing	foetal	kidney	development	in	women	with	
poorly controlled GDM or untreated GDM would be informative.
Women with and without GDM in our sample were broadly 
comparable to other obstetric cohorts reported at Monash Medical 
Centre	 with	 regards	 to	 age,	 BMI	 and	 ethnicity.47,51 We recognize 
that there were ethnic differences between women with and with‐
out GDM in our cohort, which reflects the ethnically diverse popu‐
lation receiving pregnancy care at Monash Medical Centre (where 
up	 to	 60%	 of	 births	 are	 to	 women	 born	 outside	 Australia)52 and 
the	 increased	prevalence	of	GDM	 in	women	 from	South	Asia	 and	
Southeast	Asia.53,54	In	general,	Asian	women	have	a	lower	BMI	and	
have	neonates	with	lower	birth	weights	and	fewer	LGA	infants	than	
Caucasian women.55,56 Ethnic differences may in part account for 
why	elevated	maternal	BMI,	 foetal	weight	and	birth	weight	values	
were not observed in GDM pregnancies in the present study. Other 
than ethnicity, most GDM women did not have recognized risk fac‐
tors associated with GDM. Nor were there many women with medi‐
cal and obstetric complications that may have influenced the current 
results.
Surprisingly, only two studies have previously reported foetal 
kidney volume in women with GDM. Neves et al39 serially measured 
kidney volume between 22 and 38 weeks gestation in 339 women 
without	diabetes	and	92	women	with	GDM.	Foetal	kidney	volume	
was	higher	in	GDM	pregnancies	throughout	gestation	(22‐38	weeks).	
Excessive kidney growth was observed prior to GDM diagnosis and 
subsequently, despite the fact that approximately 80% of GDM 
women achieved glycemic control. However, although 339 women 
were included in the study, sample sizes at individual time points 
were low with n ranging from 2 to 26 in the GDM group, and mater‐
nal characteristics, glucose profiles, treatment modality and foetal 
and birth weight outcomes were not reported. In a second study, 
Verburg et al38 assessed the effect of various maternal and foetal 
factors on foetal kidney volume in 1215 pregnancies. Maternal di‐
abetes	 (pre‐existing	and	GDM	combined)	was	not	associated	with	
TA B L E  3  Unadjusted	regressions	between	total	foetal	kidney	
volume and maternal and foetal characteristics
 Total foetal kidney volume
Maternal characteristics










Total kidney volume .




*P < .05. 
**P < .01. 
***P < .001. 
TA B L E  4   Multivariable regression of total foetal kidney volume 
and maternal and foetal characteristics
 
Total foetal kidney volume
B B SE β
OGTT	2‐h	glucose −0.197 0.350 −0.053
Parity 1.861 1.309 0.129
Ethnicity (Caucasian) 2.155 1.387 0.147
Estimated foetal weight 0.006 0.002 0.210* 
Adjusted	R2  0.089**   
Abbreviations:	B, unstandardized regression coefficient; B SE, standard 
error of coefficient; β, standardized regression coefficient; OGTT, oral 
glucose tolerance test.
Bold	values	represent	statistical	significance.
*P < .05. 
**P < .01. 
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foetal kidney volume at 30 weeks gestation, although only 16 cases 
of maternal diabetes were reported among these 1215 pregnancies. 
In contrast to these two previous studies, the current study presents 
data for a larger sample of 64 diabetic women, and outcomes are 
reported for women with GDM only, rather than combining poten‐
tially	confounding	results	from	women	with	GDM	and	pre‐existing	
diabetes. We report data for a range of maternal and foetal charac‐
teristics, and analysed kidney size by assessing left and right kidney 
dimensions and volumes, as well as total kidney volume and total 
volume adjusted for foetal size.
We are aware of just two studies that assess postnatal kidney 
size	in	infants	or	children	of	diabetic	mothers.	Bos	et	al57 measured 
kidney length in 20 healthy newborn controls and 20 infants born to 
women	with	Type	1	diabetes.	As	in	our	study,	diabetic	mothers	were	
tightly controlled and no differences in infant left or right kidney 
lengths were reported. Conversely, Cappuccini et al40 reported re‐
duced	renal	cortical	volume	and	microalbuminuria	in	3‐year‐old	chil‐
dren	of	women	with	pre‐existing	diabetes	(n	=	13)	and	GDM	(n	=	29),	
compared to 21 children whose mothers had not had diabetes. It is 
possible that women who had GDM in the latter study had greater 
levels of hyperglycaemia than women in the present study, as 86% of 
their participants required insulin. However, maternal glucose pro‐
files were not reported.
In conclusion, our findings indicate that a period of mild hy‐
perglycaemia prior to GDM diagnosis and treatment does not 
alter	 kidney	 volume	 at	 32‐34	 weeks	 gestation.	 Further	 studies	
to assess kidney size and function in children and adults of both 
well controlled and poorly controlled (or untreated) GDM are 
warranted to validate the effectiveness of GDM treatment pro‐
tocols—an important area of research given the limited number 
of studies in this field and the increasing number of women diag‐
nosed with GDM.
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TA B L E  5  Birth	outcomes
 
No‐GDM 
(n = 64) GDM (n = 64) Pa
GDM‐Diet & 
Exercise (n = 42)
GDM‐Insulin 
(n = 22) Pb
Birth	outcomes
Birth	weight,	g 3373 (488) 3221 (388) .07 3224 (384) 3214 (405) .16
Gestational age, wk 39.5 (1.3) 39.1 (1.2) .07 39.1 (1.1) 39.2 (1.3) .26
Birth	weight	percentile,	median	(IQR) 50	(24‐76) 40	(15‐72) .25 30	(15‐77) 40	(23‐55) .47
Caesarean birth, n (%) 17 (26.5) 21 (32.8) .67 14 (33.3) 7 (31.8) .71
Apgar	score,	1	min 8.5 (1.4) 8.3 (1.3) .12 8.3 (1.4) 8.5 (0.9) .63
Apgar	score,	5	min 8.9 (0.7) 8.9 (0.5) .99 8.9 (0.5) 9.0 (0.0) .61
Male, n (%) 31 (48.4) 30 (46.9) .91 18 (42.9) 11 (50.0) .84
Large	for	gestational	age	(>90th	centile),	n	(%) 8 (12.5) 5 (7.8) .79 3 (7.1) 2 (9.1) .67
Small for gestational age (<10th centile), n (%) 9 (14.0) 10 (15.6) .92 8 (19.0) 2 (9.1) .56
Low	birth	weight	(<2500	g),	n	(%) 2 (3.1) 1 (1.6) – 1 (2.4) 0 –
Macrosomia (birth weight > 4500 g), n (%) 1 (1.6) 0 – 0 0 –
Note: Values are mean (SD) except where indicated otherwise.
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